Literature DB >> 12925306

Suppression of DMBA-induced mouse skin tumor development by inositol hexaphosphate and its mode of action.

Krishna P Gupta1, Jaya Singh, R Bharathi.   

Abstract

Inositol hexaphosphate (IP6) or phytic acid, contained in most mammalian cells, has been shown to have anticancer and anti-cell-proliferative effects in several experimental models of carcinogenesis. We investigated the effect of topical application of IP6 on 7,12-dimethylbenzanthracene (DMBA)-induced complete carcinogenesis and on selective critical events of proliferation, differentiation, or apoptosis after DMBA exposure. IP6 inhibited skin tumor development significantly in a dose-dependent manner. IP6 induced the DMBA-inhibited transglutaminase activity. DNA synthesis, as determined by [3H]thymidine incorporation, was suppressed by IP6 in a dose-dependent manner. IP6 also inhibited thymidine kinase enzyme, which is responsible for [3H]thymidine incorporation into DNA. Our results show that topical application of IP6 inhibits DMBA-induced mouse skin tumor development and that IP6 exerts its tumor inhibitory effect probably by modulating proliferation, differentiation, or apoptosis. It seems that IP6 is an effective and potential chemopreventive agent for management of skin tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925306     DOI: 10.1207/S15327914NC4601_09

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  2 in total

1.  Protective effect of inositol hexaphosphate against UVB damage in HaCaT cells and skin carcinogenesis in SKH1 hairless mice.

Authors:  Kendra A Williams; Krishnan Kolappaswamy; Louis J Detolla; Ivana Vucenik
Journal:  Comp Med       Date:  2011-02       Impact factor: 0.982

2.  Effect of inositol hexaphosphate on the development of UVB-induced skin tumors in SKH1 hairless mice.

Authors:  Krishnan Kolappaswamy; Kendra A Williams; Cinzia Benazzi; Giuseppe Sarli; Charles G McLeod; Ivana Vucenik; Louis J DeTolla
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.